Month: January 2022

It’s engaged in manufacturing of Advanced Pharmaceutical Ingredients (APIs), Intermediates and Nutraceutical ingredients with predominance in exports. It has a market presence in 95 countries and 17,000 employees ,31 Years In Industry and is one of the leading pharmaceutical companies in the world.

Divi’s is recognized as a ‘Reliable Supplier of generic APIs (Active pharmaceuticals ingredients)’ and a trustworthy ‘Custom Manufacturer’ to Big Pharma and also is among the top API manufactures in the world.

Divi’s is the leading manufacturer of APIs(Active pharmaceuticals ingredients), Intermediates and Registered starting materials offering high quality products with the highest level of compliance and integrity to over 95 countries.

Divi’s recently reached the milestone of being one among the top 3 API manufacturers in the world and one among the top API companies in Hyderabad.

Divi’s is a Public limited company listed on the Indian stock exchange with a revenue of INR ~7050 crores (~$960M) for the year 2020-21

Advanced manufacturing facilities both in Hyderabad and Vizag have been inspected multiple times by USFDA, EU GMP (UK, Slovenia, German, Irish authorities), HEALTH CANADA, TGA, ANVISA , COFEPRIS, PMDA and MFDS health authorities.

We envision creating value for all stakeholders by manufacturing high quality Generic APIs, Custom synthesis of APIs & Intermediates along with Nutraceutical Ingredients to the Global Pharmaceutical & Nutraceutical industry through sustainable leadership in chemistry.

We at Divi’s aim to be a responsible business, adding value through our core competency in the area of chemistry while adhering to our core values and serving the immediate community and at large through our diverse social initiatives that would establish a strong foundation for a better tomorrow for all stakeholders.

The company is engaged in production of leading generic APIs, Nutraceutical ingredients and custom synthesis of APIs and intermediates for global companies.

It has a product portfolio of 122 products across various therapeutic areas.

The company derives 47% of total revenues from top 5 products. Naproxen (an anti-inflammatory drug)

contributed 18% of total sales during FY20. The company is one of the leading suppliers of this drug.

Geographical Revenue Breakup
The company derives 85% of total revenues from exports.
Presently, it earns 47% of revenues from Europe, followed by America (23%), India (15%), Asia (11%) and rest of world (4%).

The revenue share of America has gone down from 33% . In FY17 to 23% in FY20 while the revenue share of Europe has gone up from 40% to 47% in same time frame implicating larger growth from its European Business.

R&D
The company has 3 R&D facilities near its manufacturing locations. These centers are involved in development of processes for both new compounds and improvement of processes for compounds on the market.
It spent ~38 crores towards R&D in FY20 as compared to ~35 crores in FY19.
The cost fluctuates depending on R&D operations, it spent ~43 crores towards R&D in FY17.

Manufacturing Capabilities
The company has 2 manufacturing locations at Bhuvanagiri, Karnataka and Visakhapatnam, Andhra Pradesh. These 2 manufacturing locations houses 6 different manufacturing units with diverse operations.

The company has started construction of its new manufacturing facility in Kakinada, Andhra Pradesh in Dec 2020.
The company will invest 1,500 crores from internal accruals and the operations are likely to commence within 12-18 months for phase-1 of the project.

Subsidiaries
The company has 2 wholly owned subsidiaries
Divis Laboratories (USA) Inc, Europe AG in Switzerland which are engaged in marketing/ distribution of nutraceutical products to provide greater reach to customers within these regions.
The subsidiaries brought 319 crores (6%) of revenues for the company in FY20.

LEADERSHIP :

Our Leadership team includes many members of the Senior Executive team that are well supported by a very diversified team of Board of Directors.

Both the teams are accountable to our shareholders for the responsible conduct of the business and our long-term success. They also represent the interests of all our stakeholders in ensuring that we deliver quality products by putting science at the heart of everything we do.

Leadership team along with the Board of Directors are responsible for the direction, strategy, execution and administration of the company.

The Board comprises of twelve members with Dr. Ramesh B.V. Nimmagadda as Chairman.Under the leadership of Dr. Divi, the Leadership team is responsible for overseeing the business operations. Members of the Leadership team and their biographies are shown below.

Dr. Murali K. Divi (Managing Director)

Dr. Divi is the Founder and Managing Director of Divi’s Laboratories Ltd. Dr. Divi oversees major technical and financial operations of the company.

Prior to starting Divi’s, Dr. Divi had extensive experience of over 15 years in the Pharma industry and has led various Research and Manufacturing teams globally. He holds a Ph.D. degree in Pharmaceutical Sciences from Kakatiya University, India. He is also a member of the American Institute of Chemical Engineers and the American Chemical Society.

Mr. N.V. Ramana

Executive Director

Mr. Nimmagadda is the Executive Director of Divi’s Laboratories Ltd and has been with Divi’s for the past 25 years. In his role, he oversees all functions of Strategic planning, Sales and Marketing, Custom Manufacturing, Contract research and Nutraceutical ingredients development.

Prior to joining Divi’s, Mr. Nimmagadda had over 10 years of experience in the Pharmaceutical industry and was instrumental in enhancing business development for several pharma companies. He is a graduate in chemistry from Osmania University, India. He is also a Member of the American Chemical Society.

Dr. Kiran S. Divi

Whole-Time Director & Chief Executive Officer

Dr. Kiran Divi is the Director on Board & Chief Executive Officer at Divi’s Laboratories Ltd and has been with Divi’s for the past 20 years. He officially took on the role of leading Divi’s as the CEO, starting January 2020. He oversees all the Corporate functions and Operations at our manufacturing facilities. Under his direction, Divi’s has been developing high quality business strategies and plans ensuring their alignment with the short term and long term objectives.

Prior to joining Divi’s, Dr. Divi has gained extensive knowledge and understanding of the Pharmaceutical Industry with an extra focus on the US Generic Market. He has a post-graduate degree in Pharmacy from JNTU, India. He holds a Ph.D. degree from Gandhi Institute of Technology and Management, Visakhapatnam.

Mr. Madhusudana Rao Divi

Whole-Time Director (Projects)

Mr. Rao Divi is the Director of Projects at Divi’s Laboratories Ltd and has been with Divi’s for the past 20 years. He administers all aspects of manufacturing including production, engineering, sustainability and environmental management along with construction of new projects.

Prior to joining Divi’s, Mr. Rao Divi had executed several engineering construction projects and was closely involved in implementing numerous offshore and onshore constructions in India and globally. Mr. Rao Divi has a post-graduate degree in Structural Engineering from Mysore University, India.

Ms. Nilima Prasad Divi

Whole-Time Director (Commercial)

Ms. Nilima is the Director on Board – Commercial at Divi’s Laboratories Ltd and has been with Divi’s for the past 5 years. She administers all aspects of Material Sourcing and Procurement, Corporate Finance and Investor Relations.

Prior to joining Divi’s, Ms. Nilima has gained extensive commercial acumen and familiarity with material requirement planning and financing. Ms. Nilima has a Master’s Degree in International Business from Gitam Institute of Foreign Trade, India and Masters in International Finance from Glasgow University, U.K.

Company Is almost Debt Free .

It Maintains Healthy Dividend Payout Company .

ROCE : 32% in 2021 .

Promoters Holding Is More than 51.95 % .

” In Recent Correction Stock Price is Available at Very Cheap Valuations . If Once Markets Starts Recovering its Will Gain Very Fast . Take Price as Advantage and Buy at per Your Risk “.

If Any New Investors Wants To Open New Demat Account Click on this Link  .

Like Our Facebook Page .

All Information is For Study Purposes Only .

Company Name : DIVI’S LABORATORIES LTD .

CMP : 3941/- ( On 30.01.2022)

Target : Short Term (6 Months to 1 Year ) : 4800 – 5,400/++ .

Long Term (2 – 5 Years of Time Frame ) : 8,500 – 10,300 ++

Based on Technical Charts

Source of Data : https://www.divislabs.com/ & https://www.screener.in/

Disclaimer: I am Not a SEBI REGISTERED ANALYST. This Website & Its Owner, Creator & Contributor is Neither a Research Analyst nor an Investment Advisor and Expressing Option Only as an Investor in Indian Equities. All trading strategies are used at your own risk.

He/ She are Not Responsible for any Loss a Rising out of any Information, Post or Opinion Appearing on this Website. Investors are advised to do Own Due Diligence or Consult Financial Consultant before acting on Such Information. Author of this Website not providing any Paid Service and not Sending Bulk mails/SMS to Anyone. Information is in no way guaranteed. No guarantee of any kind is implied or possible where projections of future conditions are attempted. Investment/Trading in securities Market is subject to market risk.

In our Previous Posts We Have Already mentioned about this stock . But again we are Going to Suggest This Stock Due to Its Returns Given in Last 8 Months @ 60 % ++ Returns With In 1 Year.

Click Here for Previous Post .

Stock Trading at 2019 PE at 47.60 Which is Very Cheap and Giving very Good Opportunity For entry .

This Stock is Very Good for Both short Term & Long Term also .

Preferable for Both Short Term & Long Term Investors also .

Company is almost Debt free .

Very Good Dividend Paying Company Year On Year Basis .

ROCE % From Past 10 Years is above 34 % which is Excellent .

Promoters Holding Is More than 74 % .

Risk Free Company – Instead of Buying Less Priced or More Taking More Risk Stock its Better to Buy Such Stock is Better as per My View .

If Any New Investors Wants To Open New Demat Account Click on this Link  .

Like Our Facebook Page .

All Information is For Study Purposes Only .

Company Name : ABBOTT INDIA .

CMP : 16065/-

Best Buy at : 14,900 – 15,800 .

Target : Short Term (6 Months to 1 Year ) – 18,000 – 20,200/++ .

Long Term (2 – 3 Years of Time Frame ) : 22,000 – 24,000 ++

Note : It Will always Gives Good Time to Enter .

Based on Technical Charts

Disclaimer: I am Not a SEBI REGISTERED ANALYST. This Website & Its Owner, Creator & Contributor is Neither a Research Analyst nor an Investment Advisor and Expressing Option Only as an Investor in Indian Equities. All trading strategies are used at your own risk.

He/ She are Not Responsible for any Loss a Rising out of any Information, Post or Opinion Appearing on this Website. Investors are advised to do Own Due Diligence or Consult Financial Consultant before acting on Such Information. Author of this Website not providing any Paid Service and not Sending Bulk mails/SMS to Anyone. Information is in no way guaranteed. No guarantee of any kind is implied or possible where projections of future conditions are attempted. Investment/Trading in securities Market is subject to market risk.